Paper
Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy

https://doi.org/10.1016/0959-8049(93)90003-XGet rights and content

Abstract

Serial IGF-1 levels in patients prior to and during adjuvant tamoxifen (TAM) treatment were followed in a retrospective study. Serum IGF-1 levels were determined by radioimmunoassay in 19 patients taking TAM and 19 controls, matched for age, body weight and other treatments. IGF-1 levels at 2 years were significantly lower in TAM patients (P ⩽ 0.05) compared to control patients. We observed a significant mean drop from pretreatment to treatment IGF-1 levels by 19.9% in the TAM group (P ⩽ 0.005), but also noted a mean 11.4% decline in the control group (P ⩽ 0.025). A subgroup analysis suggested that premenopausal were relatively resistant to the IGF-1 lowering effects of TAM as compared to postmenopausal women.

References (30)

  • CA O'Brian et al.

    Inhibition of protein kinase C by tamoxifen

    Cancer Res

    (1985)
  • H-Y P Lam

    Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase

    Biochem Biophys Res Commun

    (1984)
  • R Mandeville et al.

    In vitro stimulation of human NK activity by an oestrogen antagonist (tamoxifen)

    Eur J Cancer Clin Oncol

    (1984)
  • MN Pollack

    Therapeutic implications of recent growth factor research

  • R Furlanetto et al.

    Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture

    Cancer Res

    (1984)
  • Cited by (49)

    • Circadian aspects of growth hormoneinsulin-like growth factor axis function in patients with lung cancer

      2012, Clinical Lung Cancer
      Citation Excerpt :

      IGFs have properties of tissue growth factors but also have additional well-recognized functions as hormones that regulate growth and energy metabolism at the whole organism level.39 IGF1 type I receptor (IGFIR) is commonly expressed by neoplastic cell lines and human cancers, and many cancer cell lines are mitogenically responsive to physiologic concentrations of IGF1.40-44 Although the bulk of circulating IGF1 and IGF2 is produced in the liver, these peptides are frequently expressed in neoplastic tissue, so they might influence cancers through autocrine, paracrine, or endocrine mechanisms.

    View all citing articles on Scopus
    View full text